Search results
Results from the WOW.Com Content Network
The long-term effects on mental health disorders in later life of chronic use of methylphenidate is unknown. [205] A 2009 FDA review of 49 clinical trials found that approximately 1.5% of children in clinical trials of medications for ADHD had experienced signs or symptoms of psychosis or mania.
Serious side effects may include anaphylaxis, liver problems, depression, and muscle breakdown. [4] [5] Use in pregnancy and breastfeeding is of unclear safety. [10] Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic ...
A 2015 study examined the long-term effects of stimulant medication for ADHD, and reported that stimulants are a highly effective treatment for ADHD in the short term when used properly. [89] The findings for long term effects were limited. However, this study concluded that stimulant medication is a safe and effective treatment for ADHD.
Little is known about the long-term side effects of hormone or puberty blockers in children with gender dysphoria. Although puberty blockers are known to be safe and physically reversible treatment if stopped in the short term, it is also not known whether hormone blockers affect the development of factors like bone mineral density, brain ...
Soon after the meeting to deal with, and put aside, the concerns about the drug’s safety when taken by seniors, it became clearer that serious side effects in children might be an equally significant problem. The Janssen doctors and statisticians now had more complete results from the long-term study of children and adolescents using Risperdal.
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [1] [3] It is a combination of bempedoic acid and ezetimibe. [1] [2] The most common side effects are hyperuricemia (high blood levels of uric acid) and constipation. [2]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Some severe side effects with long-term consequences may include pancreatitis, acute kidney injury, gallstones, gallbladder disease, diabetic retinopathy, and an increased heart rate. Semaglutide ...